Introduction
============

CYP3A4, the most abundant cytochrome P450 (CYP450) enzyme in the human liver and small intestine, is responsible for the metabolism of about 50% of all marketed drugs and many endogenous molecules (Danielson [@b8]). Changes in physiological and pathophysiological conditions including diabetes can affect drug metabolism and disposition (Lam et al. [@b20]). Several studies have shown that uncontrolled diabetes mellitus alters the disposition of a number of drugs (Zysset and Wietholtz [@b42]), potentially increasing the risk for drug toxicity and side effects, or decreasing drug efficacy. Diabetes mellitus may be defined as a commonly occurring disease in which plasma glucose control is defective because of insulin deficiency or decreased target-cell responsiveness to insulin (Watkins and Sanders [@b38]). Type 1 diabetes (T1D), which accounts for about 5--10% of all cases of diabetes, is the consequence of pancreatic *β*-cells destruction and usually leads to absolute insulin deficiency (Daneman [@b7]). Type 2 diabetes (T2D) is a metabolic disorder characterized by insulin resistance mostly related to lifestyle (obesity and sedentary behavior) with a weaker genetic component (Ripsin et al. [@b27]). In 2011, over 350 million people worldwide were affected by this widespread chronic disease and its prevalence is expected to increase to approximately 550 million by 2030 (Whiting et al. [@b39]). Both T1D and T2D are known to modulate CYP3A activity and/or expression in humans and in animal models (Goldstein et al. [@b14]; Dong et al. [@b10]; Kudo et al. [@b18]). Streptozotocin-induced diabetes is a widely used mouse model of the disease, as this chemical selectively destroys pancreatic *β*-islet cells, further leading to a corresponding increase in blood glucose and pathological changes commonly seen in human with T1D (Gandhi et al. [@b13]). The *db/db* mouse is a routinely used animal model characterized by a mutation of the leptin receptor leading to a metabolic disturbance closely resembling T2D (Lam et al. [@b20]). In the present study, these two mice models of T1D and T2D have been used to better understand the effect of these two different diseases on the hepatic and intestinal metabolism of domperidone, a specific substrate of CYP3As with a complex metabolic profile (Simard et al. [@b31]; [Appendix](#app1){ref-type="app"}). An additional functional hepatic CYP3a-specific assay with testosterone was performed. Hepatic transcription and expression of CYP3a were also measured.

Materials and Methods
=====================

Animals
-------

Male 7 weeks-old BKS.Cg-m +/+ Lepr^db^/J mice (*db/db*: T2D) and control C57BLKS/J wild-type mice were purchased from The Jackson Laboratory (Bar Harbor, ME). In a subgroup of wild-type mice, T1D was induced after one week (8 weeks-old) with intraperitoneal injections of streptozotocin (Sigma-Aldrich, St. Louis, MO) 50 mg kg^−1^ day^−1^ during 10 days. The animals were housed under a constant 12 h dark/light cycle and were given standard chow and water ad libitum. At 12 weeks-old, blood samples were collected via the submandibular vein and the animals were sacrificed by cervical dislocation. Livers and small intestine were quickly harvested, washed with ice-cold phosphate-buffered saline (PBS), snap-frozen in liquid nitrogen and kept at −80°C. These experiments were carried out in accordance with the Declaration of Helsinki and with the Guide to the Care and Use of Experimental Animals of the Canadian Council on Animal Care.

Microsome preparation
---------------------

The liver microsomes were prepared by differential centrifugation as described previously (Inaba and Kovacs [@b15]). The intestinal microsomes were extracted based on Bruyère's method (Bruyère et al. [@b3]), with modifications. Briefly, small intestines from two mice were pooled and homogenized in 5 mL of PBS containing 20% (v/v) glycerol, 0.1% protease inhibitor cocktail (Sigma-Aldrich), 5 mmol/L histidine, 0.25 mol/L sucrose, 1 mmol/L ethylenediaminetetraacetic acid (EDTA), and then centrifuged at 10,000 *g* for 15 min, 4°C. The supernatant was collected and then centrifuged for 60 min at 100,000 *g*, 4°C. Microsomal pellets were reconstituted in a 50 mmol/L phosphate buffer (pH 7.0) containing 20% glycerol, 0.1% protease inhibitor cocktail, aliquoted and stored at −80°C. The protein content was determined with the DC™ protein assay (Bio-Rad, Mississauga ON, Canada).

Domperidone metabolism assay
----------------------------

Standard incubations and high performance liquid chromatography (HPLC) measurement of domperidone and its metabolites were performed as previously described (Patoine et al. [@b25]) with modification of the mobile phases as follows: A- H~2~O and B- 20 mmol/L phosphate buffer, acetonitrile, methanol, triethylamine (62:23:15:0.1); final pH 7.0. The elution gradient used was the following: 0--6 min, 10% A; 7--26 min, 100% B. Variable flow-rates were imposed: 0--10 min, 1 mL/min, 11--13 min, 1.6 mL/min, 13--26 min, 1.7 mL/min.

Testosterone metabolism assay
-----------------------------

Standard incubations containing testosterone 200 *μ*mol/L were performed. 11-*β*-OH-testosterone was used as internal standard. The measurement of testosterone, 6-*β*-OH-testosterone and 11-*β*-OH-testosterone was performed by a slight modification of a reported method (Mohri and Uesawa [@b23]). Mobile phase consisting of H~2~O, methanol, acetonitrile (31.6:58.9:9.5) containing 0.05% of phosphoric acid was used.

RNA extraction and cDNA synthesis
---------------------------------

Total RNA was extracted from 100 mg of frozen hepatic tissue using Trizol® reagent (Invitrogen, Burlington ON, Canada). Purified RNA was treated with DNase (DNA-free kit: Invitrogen). cDNA was prepared with 1 *μ*g of total RNA using the iScript™ cDNA synthesis kit (Bio-Rad).

Reverse transcription quantitative polymerase chain reaction
------------------------------------------------------------

The level of gene expression in tissues was evaluated with the iQ SYBR green supermix (Bio-Rad). Gene-specific primers were designed with the VectorNTI software (Invitrogen) to amplify CYP3a11, 3a13, 3a25, 3a44, CAR, PXR (pregnane X receptor) and two reference genes; RPLP0 and *β*-Actin. The primers and PCR conditions used for amplifications were as described in Table [1](#tbl1){ref-type="table"}. Primers were optimized and validated with standard curves to obtain efficiencies between 90--105%. Amplicons were sequenced to confirm the identity of the fragment. A dissociation curve protocol was linked to every PCR assay to ensure the specificity of the PCR product. Relative quantification was calculated with methods that correct for differences in amplification efficiency (Pfaffl [@b26]) and allow the use of multiple reference genes (Vandesompele et al. [@b35]).

###### 

Primer sequences used for the RT-qPCR analysis and conditions

                                                        PCR conditions   
  -------------- -------------------------------- ----- ---------------- --------------
  CYP3a11-F      GCC ATT TTT AGG CAC TGT GCT GA   124   95°C, 15 sec     60°C, 30 sec
  CYP3a11-R      TGT GAC AGC AAG GAG AGG CGT                             
  CYP3a13-F      GAC CTG ATC CCA AAC TTT TCC      211   95°C, 15 sec     60°C, 30 sec
  CYP3a13-R      TCC TTC TCC TAA TCC CTG CC                              
  CYP3a25-F      TGG GCA TAC TCA ACT TTC C        148   95°C, 15 sec     60°C, 30 sec
  CYP3a25-R      CCA CAA GAA TCA GAA GGT                                 
  CYP3a44-F      CTG AGC TTT CTC AGT GTC TGT G    102   95°C, 15 sec     60°C, 30 sec
  CYP3a44-R      GAT CCC ATG AGA AAC GGT GAA G                           
  Beta-actin-F   TGT TAC CAA CTG GGA CGA CA       165   95°C, 15 sec     60°C, 30 sec
  Beta-actin-R   GGG GTG TTG AAG GTC TCA AA                              
  CAR-F          CTC AAG GAA AGC AGG GTC AG       168   95°C, 15 sec     60°C, 30 sec
  CAR-R          GGT CTC CAC ACA CCA CAC AG                              
  PXR-F          AGG GGG AAA TCC AAC AAA AG       184   95°C, 15 sec     60°C, 30 sec
  PXR-R          ACA CGG CAG ATT TGA AGA CC                              
  RPLP0-F        ATC ACA GAG CAG GCC CTG CA       96    95°C, 15 sec     57°C, 30 sec
  RPLP0-R        CAC CGA GGC AAC AGT TGG GT                              

Western Blot
------------

Western blots were performed as previously described (Patoine et al. [@b25]) to assess CYP3a protein expression. Briefly, samples of frozen liver were homogenized in an ice-cold lysis buffer (10 mmol/L Tris-HCl \[pH 7.4\], 0.32 mol/L sucrose, 1 mmol/L EDTA, 1 mmol/L dithiothreitol, 0.1% of a protease inhibitor cocktail from Sigma-Aldrich). Western blot analysis of 5 *μ*g of proteins was used to assess the levels of CYP3a protein in the livers. The membrane was incubated overnight at 4°C with anti-rat-CYP3a2 polyclonal antibody (1:1000; EMD Millipore, Billerica MA). The membrane was washed and then incubated with a secondary antibody conjugated with horseradish peroxidase. Immunodetection was done with the Luminata™ Crescendo Western HRP Substrate (EMD Millipore). Normalization against the total lane density of loaded proteins was used with TGX Stain-Free gels (Bio-Rad) according to the newly published methods (Taylor et al. [@b33]; Taylor and Posch [@b32]).

Data analysis
-------------

One-way analysis of variance (ANOVA) followed by a Tukey test or a Mann--Whitney test (when the normality test failed) were used to evaluate the statistical differences between groups (SigmaPlot 12.5, Jandel Scientific Software, San Rafael, CA). All the results were expressed as mean ± SEM. Level of statistical significance was set at *P* \< 0.05.

Results and Discussion
======================

The aim of the present study was to determine the effect of T1D and T2D on CYP3a in mouse. To this end, two different mice models of T1D and T2D were used. To confirm phenotypes, weight and a number of blood parameters were measured (Table [2](#tbl2){ref-type="table"}). Figure [1](#fig01){ref-type="fig"} shows hepatic (A) and intestinal (B) CYP3a activities using domperidone and hepatic (C) CYP3a activity using testosterone. Figure [2](#fig02){ref-type="fig"} shows hepatic steady-state levels of CYP3a (A), PXR and CAR (B) mRNAs and protein expression (C).

###### 

Body weight and biochemical parameters at sacrifice (12 weeks-old). (\*\**P* \< 0.01, \*\*\**P* \< 0.001 vs. control)

                             Control                  T1D                            T2D
  -------------------------- ------------------------ ------------------------------ ------------------------------
  Weight (g)                 23.5 ± 0.5 (*n* = 17)    19.9 ± 0.3\*\*\* (*n* = 17)    39.8 ± 1.2\*\*\* (*n* = 20)
  Glycemia (mmol/L)          8.2 ± 0.7 (*n* = 17)     28.3 ± 0.9\*\*\* (*n* = 17)    31.3 ± 0.6\*\*\* (*n* = 17)
  Insulinemia (ng/mL)        0.67 ± 0.06 (*n* = 17)   0.18 ± 0.04\*\*\* (*n* = 12)   3.90 ± 0.50\*\*\* (*n* = 18)
  HDL-C (mmol/L)             2.10 ± 0.05 (*n* = 16)   3.54 ± 0.45\*\*\* (*n* = 15)   3.18 ± 0.13\*\*\* (*n* = 15)
  Triglyceridemia (mmol/L)   1.67 ± 0.07 (*n* = 16)   2.58 ± 0.47\*\*\* (*n* = 17)   2.33 ± 0.22\*\* (*n* = 17)
  Cholesterolemia (mmol/L)   2.32 ± 0.17 (*n* = 16)   4.40 ± 0.45\*\*\* (*n* = 17)   3.77 ± 0.11\*\*\* (*n* = 17)

![(A) Hepatic microsomal CYP3a activity: This figure shows peak-height ratios of metabolites of domperidone to internal standard for the three groups. Formation of four of the five metabolites (M1-4) were significantly increased in the T1D group (M1: 0.417 ± 0.071, M2: 0.199 ± 0.011, M3: 0.818 ± 0.117, M4: 0.201 ± 0.019, M5: 0.178 ± 0.018; *n* = 17) when compared to the control group (M1: 0.158 ± 0.014, M2: 0.090 ± 0.003, M3: 0.384 ± 0.033, M4: 0.109 ± 0.005, M5: 0.152 ± 0.011; *n* = 14). In the T2D group, M2 and M4 were significantly increased while M5 was significantly decreased (M1: 0.209 ± 0.029, M2: 0.171 ± 0.007, M3: 0.487 ± 0.065, M4: 0.147 ± 0.011, M5: 0.093 ± 0.006; *n* = 18). Metabolites of domperidone were not formally identified. (B) Intestinal microsomal CYP3a activity: Formation of the four metabolites was significantly increased in both T1D (M1: 0.113 ± 0.013, M2: 0.054 ± 0.007, M3: 0.389 ± 0.040, M4: 0.077 ± 0.007; *n* = 8) and T2D (M1: 0.093 ± 0.017, M2: 0.032 ± 0.010, M3: 0.338 ± 0.065, M4: 0.075 ± 0.011; *n* = 6) groups when compared to the control group (M1: 0.004 ± 0.004, M2: 0.002 ± 0.002, M3: 0.039 ± 0.013, M4: 0.015 ± 0.006; *n* = 8), except for M4 in the T2D group. (C) Hepatic microsomal CYP3a activity: This figure shows peak-height ratios of the CYP3a-catalized metabolite of testosterone to internal standard for the three groups. Formation of 6-*β*-OH-testosterone was significantly increased in both T1D and T2D groups when compared to control group (0.588 ± 0.063, 0.661 ± 0.098 vs. 0.277 ± 0.018; *n* = 15, 17, 16, respectively)](prp20002-e00082-f1){#fig01}

![(A) Relative steady-state levels of CYP3a mRNAs in mouse livers. A significant increase of CYP3a11 and CYP3a13 was observed for both T1D and T2D groups when compared to the control group (3a11: 3.31 ± 0.24, 1.99 ± 0.22 vs. 1.00 ± 0.10; *n* = 17, 20, 18 respectively) (3a13: 3.25 ± 0.10, 3.19 ± 0.26 vs. 1.00 ± 0.05; *n* = 17, 20, 17 respectively), and for CYP3a44 in T1D group (1.68 ± 0.14, 0.95 ± 0.10 vs. 1.00 ± 0.11; *n* = 17, 20, 17 respectively). No significant difference was observed for CYP3a25 (0.93 ± 0.05, 0.89 ± 0.09 vs. 1.00 ± 0.11; *n* = 17, 19 respectively). (B) Relative steady-state levels of PXR and CAR mRNAs in mouse livers. A significant increase of PXR and CAR was observed in both T1D and T2D groups when compared to the control group (PXR: 1.67 ± 0.14, 2.04 ± 0.20 vs. 1.00 ± 0.05; *n* = 17, 19, 17 respectively) (CAR: 3.43 ± 0.16, 2.44 ± 0.24 vs. 1.00 ± 0.08; *n* = 17, 15 respectively). (C) Relative expression of CYP3a proteins in mouse livers. On the left, a significant increase was observed in both T1D and T2D groups when compared to the control group (1.35 ± 0.106, 1.62 ± 0.11 vs. 1.00 ± 0.11; *n* = 17, 18, 17 respectively). On the right are the representative images of the ChemiBlot of CYP3a and the total proteins loaded for the three groups.](prp20002-e00082-f2){#fig02}

Type 1 diabetes
---------------

Mice with T1D displayed blood parameters with typical increases of glycemia, cholesterolemia, and triglyceridemia as well as about 75% decrease of insulinemia versus controls (Table [2](#tbl2){ref-type="table"}). Hepatic CYP3a activity monitored through metabolism of domperidone and testosterone was increased (Fig. [1A and C](#fig01){ref-type="fig"}). These results are consistent with many other studies. Sakuma et al. ([@b29]) found increases in CYP3a activity and mRNA expression in streptozotocin-induced T1D in mice, both at 2 and 4 weeks after induction. Increased drug-metabolizing activity of CYP3a1 was also shown in rats with either alloxan- or streptozotocin-induced T1D (Kim et al. [@b16]; Lee et al. [@b21]). Similar rises of the CYP3A-related metabolism (Kudo et al. [@b19]) and mRNA transcription were also described and proved to be CAR-mediated (Dong et al. [@b10]). Interestingly, this is also consistent with our results showing significantly increased mRNA transcription of CAR and PXR in T1D (Fig. [2B](#fig02){ref-type="fig"}). As it turned out, in the present study, increases in transcription of CYP3a11, 3a13 and 3a44 (but not 3a25) were observed (Fig. [2A](#fig02){ref-type="fig"}). It has been reported that each CYP3a isoenzyme has a different sensitivity to diabetes and that these isoforms are not controlled by uniform regulatory mechanisms (Sakuma et al. [@b29]), which is consistent with our CYP3a25 mRNA transcription results. Moreover, western blot experiments revealed increase in CYP3a protein expression (Fig. [2C](#fig02){ref-type="fig"}) which fairly correlates with the previously observed increase in CYP3a activity and mRNA transcription induced by T1D. As seen for liver metabolism, intestinal CYP3a activity was significantly increased ([Fig 1B](#fig01){ref-type="fig"}).

Type 2 diabetes
---------------

Mice with T2D had severe obesity, hyperglycemia, hypercholesterolemia, hypertriglyceridemia, and hyperinsulinemia. Even if insulin levels at 12 weeks-old were still elevated, they were reduced sixfold compared to those at 8 weeks-old (22.57 ± 2.94 vs. 3.90 ± 0.50 ng mL^−1^, *P* \< 0.001) indicating that diabetes had evolved toward a more severe stage. A significant increase in hepatic formation of two of the five CYP3A-related metabolites of domperidone (M2 and M4), as well as a significant decrease in the formation of M5, were observed (Fig. [1A](#fig01){ref-type="fig"}). This is consistent (for M2 and M4) with the increase in protein expression of CYP3a (Fig. [2C](#fig02){ref-type="fig"}). In human, it is recognized that CYP3A4 has six substrates recognition site (SRS) (Roussel et al. [@b28]; Domanski et al. [@b9]; Xue et al. [@b40]). It is possible that these SRS are differently modified by diabetes, thereby explaining the nonuniform effect on the formation of the metabolites. Moreover, a compensatory effect cannot be ruled out. Metabolism of testosterone to 6-*β*-OH-testosterone was also significantly increased (Fig. [1C](#fig01){ref-type="fig"}), and correlates with the observed increase in CYP3a protein expression induced by T2D. Similar results were obtained by other groups. Indeed, increased CYP3a-mediated drug-metabolizing activity was also shown in rats with T2D induced by a combination of streptozotocin and high-fat diet (Chen et al. [@b4]), in Tsumura Suzuki Obese Diabetes (TSOD) mice with T2D and obesity (Kudo et al. [@b18]), and in C57BL/6J mice with T2D (Koide et al. [@b17]). Interestingly, mRNA of CAR, PXR, CYP3a11, and 3a13 were significantly increased while 3a25 and 3a44 were unchanged (Fig. [2A--B](#fig02){ref-type="fig"}). Intestinal CYP3a activity was also increased (Fig. [1B](#fig01){ref-type="fig"}) in *db/db* mice. In vitro studies have shown that hypertonicity of ambient osmotic environment in cultured intestinal human cells increases expression of CYP3A (Chuang and Ito [@b6]). Furthermore, after spontaneous ingestion of solid food with free access to water, rodent intestinal osmolality may reach 600--800 mOsm kg^−1^, which is at least a twofold increase compared with the measured plasma osmolality of 300 mOsm kg^−1^ (Osaka et al. [@b24]). Given that both mice models are characterized by robust increases in food intake, one due to classical T1D-associated hyperphagia and the other due to a *db/db* mutation that suppresses leptin receptor signaling, we speculate that this constant hyperosmolar stimulation may be in part responsible for the augmentation of CYP3a intestinal metabolism.

Contradictions exist in the literature regarding the effect of diabetes on P450 activity in humans and in animal models, potentially due to a number of factors including age, gender, disease duration and degree of diabetes control (Wang et al. [@b37]). The molecular mechanisms underlying these changes in drug biotransformation have not been fully characterized yet (Dostalek et al. [@b11]). Different laboratories have reported either decreased (Ma et al. [@b22]; Thummel and Schenkman [@b34]; Yamazoe et al. [@b41]) or increased (Barnett et al. [@b2]; Shimojo et al. [@b30]; Verrecchia and Guaitani [@b36]) CYP3A protein expression following STZ treatment. Cheng and Morgan (Cheng and Morgan [@b5]) proposed that these conflicting data on diabetic regulation of CYP3A proteins could be due to different specificities of the antibodies used for the Western blot assays, coupled with differential regulation of CYP3A family members. It has been shown that CYP3A4 expression and activity is significantly reduced in livers from diabetic donors as compared to nondiabetic counterparts (Dostalek et al. [@b11]), and that diabetes mellitus reduces clearance of both atorvastatin lactone (Dostalek et al. [@b12]) and cyclosporine (Akhlaghi et al. [@b1]), two typical CYP3A4 substrates in humans. Collectively, it is evident that marked species-related differences exist in the modulation of P450 3A activity in response to diabetes. Obviously, acting as an additional confusing effect, is the fact that most people with diabetes end up being treated with oral hypoglycemic agents or insulin, which can modulate their pathophysiological state, along with 'disease-modifying' interventions such as diet and exercise (Cheng and Morgan [@b5]).

Overall, this study demonstrates that, although differences exist in the pathophysiological insults associated with T1D and T2D, these two distinct diseases may have similar effects on CYP3a regulation, ultimately leading to variability in endogenous substrates metabolism and drug response. Given the severity of the comorbidities associated with T1D and T2D, considerable medical and research resources have been allocated in an effort to minimize these debilitating complications. Yet, important and potentially life-threatening complications specifically resulting from drug-related toxicity or inefficacy in diabetic patients have passed under the radar. To fully elucidate the molecular mechanism(s) by which diabetes and other pathophysiological factors affect drug metabolism, further and complete characterization of inflammation mediators, nuclear receptors, adipokines, insulin signaling pathway, apoptosis, and liver metabolic dysregulation will be required.
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To further confirm the major involvement of CYP3A in domperidone metabolism, we performed inhibition study with our mice microsomes using ketoconazole, furafylline, sulfaphenazole, ciprofloxacin, and quinidine. Figure [S1](#SD1){ref-type="supplementary-material"} demonstrates strong inhibition of domperidone metabolism only with ketoconazole. We also performed inhibition study and included a fifth metabolite of domperidone; M5. In Figure [S2](#SD2){ref-type="supplementary-material"}, we can see that the formation of M5 is also strongly inhibited by ketoconazole.
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Additional Supporting Information may be found in the online version of this article:

###### 

**Figure S1.** Figure [S1](#SD1){ref-type="supplementary-material"} shows the percentage of control activity of four of the five metabolities (M1-4) in pooled mouse liver microsomes using standard inhibitors such as ketoconazole (CYP3A), furafylline (CYP1A), sulfaphenazole (CYP2C), ciprofloxaxin (CYP1A) and quinidine (CYP2D). Strong inhibition was observed only with ketoconazole.

###### 

**Figure S2.** Figure [S2](#SD2){ref-type="supplementary-material"} shows the effect of ketoconozole on domperidone metabolism in pooled mouse liver microsomes. Strong inhibition of the formation of the five metabolities of domperidone was observed with ketoconazole 10 μM. The inhibitory effect was also confirmed by a weaker biotransformation of domperidone.
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